Table 18:
Prostate Cancer Mortality for ERSPC Participating Countries (Core Age Group, 55–69 Years)
| Country, Median Follow-Up, Years | Screening Arm | Control Arm | RR (95% CI) | ARD/10,000 P-YRs (Screen – Control) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PC Cases | Cumulative Incidence % | PC Deaths | P-YRs | Rate /10,000 P-YRs | PC Cases | Cumulative Incidence % | PC Deaths | P-YRs | Rate /10,000 P-YRs | |||
| Netherlands, 11.0 | 2,478 | 11.7 | 69 | 186,082 | 3.7 | 1,152 | 5.4 | 97 | 184,999 | 5.2 | 0.71 (0.52–0.96) | −1.5 |
| Belgium, 12.1 | 504 | 9.7 | 22 | 48,270 | 4.6 | 405 | 7.8 | 25 | 47,102 | 5.3 | 0.86 (0.48–1.52) | −0.7 |
| Sweden, 14.0 | 1,139 | 11.4 | 39 | 73,663 | 5.3 | 715 | 7.2 | 70 | 74,031 | 9.5 | 0.56 (0.38–0.83) | −4.2 |
| Finland, 11.0 | 2,838 | 8.9 | 139 | 333,535 | 4.2 | 3,175 | 6.6 | 237 | 504,263 | 4.7 | 0.89 (0.72–1.09) | −0.5 |
| Italy, 10.7 | 394 | 5.3 | 19 | 72,315 | 2.6 | 267 | 3.6 | 22 | 71,691 | 3.1 | 0.86 (0.46–1.58) | −0.5 |
| Spain, 10.6 | 88 | 4.8 | 2 | 10,969 | 1.8 | 33 | 1.8 | 1 | 11,819 | 0.8 | 2.15 (0.20–23.77) | 1.0 |
| Switzerland, 8.2 | 497 | 9.6 | 9 | 39,398 | 2.3 | 237 | 4.6 | 10 | 39,147 | 2.6 | 0.89 (0.36–2.20) | −0.3 |
Abbreviations: ARD, absolute risk difference; CI, confidence interval; ERSPC, European Randomized Study of Screening for Prostate Cancer; PC, prostate cancer; P-YR, person-year; RR, relative risk. Source: Schroder et al, 2012. (55)